Abstract
Early in the COVID-19 pandemic predictions of a worldwide ventilator shortage prompted a worldwide search for solutions. The impetus for the scramble for ventilators was spurred on by inaccurate and often unrealistic predictions of ventilator requirements. Initial efforts looked simply at acquiring as many ventilators as possible from national and international sources. Ventilators from the Strategic National Stockpile were distributed to early hotspots in the Northeast and Northwest United States. In a triumph of emotion over logic, well-intended experts from other industries turned their time, talent, and treasure toward making a ventilator for the first time. Interest in shared ventilation (more than one patient per ventilator) was ignited by an ill-advised video on social media that ignored the principles of gas delivery in deference to social media notoriety. With shared ventilation, a number of groups mistook a physiologic problem for a plumbing problem. The United States government invoked the Defense Production Act to push automotive manufacturers to partner with existing ventilator manufacturers to speed production. The FDA granted emergency use authorization for “splitters” to allow shared ventilation as well as for ventilators and ancillary equipment. Rationing of ventilators was discussed in the lay press and medical literature but was never necessary in the US. Finally, planners realized that staff with expertise in providing mechanical ventilation were the most important shortage. Over 200,000 ventilators were purchased by the United States government, states, cities, health systems, and individuals. Most had little value in caring for patients with COVID-19 ARDS. This paper attempts to look at where miscalculations were made, with an eye toward what we can do better in the future.
- mechanical ventilation
- COVID-19
- disaster medicine
Footnotes
- Correspondence: Richard D Branson MSc RRT FAARC, University of Cincinnati, 231 Albert Sabin Way, ML #0558, Cincinnati, OH 45267. E-mail: richard.branson{at}uc.edu
↵† Deceased.
Mr Branson discloses relationships with Daedalus Enterprises, Inogen, Lungpacer, Ventec Life Systems, and Zoll Medical. He is Editor-in-Chief of Respiratory Care.
Mr Branson presented a version of this paper as part of the New Horizons Symposium: COVID-19 Lessons Learned at AARC Congress 2021 LIVE!, held virtually December 3, 2021.
- Copyright © 2023 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.